Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

4(50.0%)

8Total

Phase 2(4)

Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06552416Phase 1Recruiting

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

Role: lead

NCT04511130Phase 2Terminated

Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

Role: lead

NCT05798897Phase 1Recruiting

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

Role: lead

NCT06549751Phase 1Not Yet Recruiting

MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Role: lead

NCT02978222Phase 2Terminated

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Role: lead

NCT02764333Phase 2Completed

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Role: collaborator

NCT02593227Phase 2Completed

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

Role: lead

NCT01632332Phase 1Completed

Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

Role: collaborator

All 8 trials loaded